Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Actelion Q1 GAAP Profit Slumps; Backs 2012 Core Earnings View - Quick Facts

Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) reported a plunge in its first-quarter GAAP net income to 45.06 million Swiss francs or 0.38 Swiss francs per share from the prior year's 146.29 million Swiss francs or 1.20 Swiss francs per share. Core earnings per share declined 31% to 0.66 Swiss francs during the latest quarter.

Total net revenue slipped to 417.47 million Swiss francs from 528.23 million Swiss francs a year earlier.

Product sales for the quarter reached 415.8 million Swiss francs, compared with 450.1 million Swiss francs last year, down by 4% in local currencies. In addition, the company reaffirmed its 2012 flat core earnings forecast.

Click here to receive FREE breaking news email alerts for Actelion Ltd., and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. (HPQ) said Wednesday after the markets closed that its third quarter profit fell 29% from last year, hurt mainly by higher restructuring charges even as revenue grew 1%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue beat analysts' forecast. Stocks fluctuated over the course of the trading day on Wednesday before ending the session mostly higher. The Dow and the S&P 500 both finished the day in positive territory, although the tech-heavy Nasdaq posted a modest loss. President Barack Obama spoke harshly of the terrorist group allegedly responsible for the execution of American freelance journalist James Foley in a statement on Wednesday. Obama described the group known as the Islamic State of Iraq and the Levant, or ISIL, as a cancer that needs to be extracted.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.